Review article: biological drugs in Crohn's disease.

about

Traditional corticosteroids for induction of remission in Crohn's disease Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure.The opioid antagonist naltrexone improves murine inflammatory bowel disease.

P2860

Q24242955-114332E9-DAC4-4EC6-8E96-A86BB8EA2257 Q36151324-B6FDD21C-AD7E-47DA-A223-4F543F267C75 Q44339195-996EB3E4-5C68-4420-8AF0-DC002B793B29

P2860

Review article: biological drugs in Crohn's disease.

Item

http://www.wikidata.org/entity/Q36589442

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Review article: biological drugs in Crohn's disease.

@ast

Review article: biological drugs in Crohn's disease.

@en

type

Item

label

Review article: biological drugs in Crohn's disease.

@ast

Review article: biological drugs in Crohn's disease.

@en

prefLabel

Review article: biological drugs in Crohn's disease.

@ast

Review article: biological drugs in Crohn's disease.

@en

P1476

Review article: biological drugs in Crohn's disease.

@en

P2093

Kamm MA

http://www.w3.org/2001/XMLSchema#string

P2860

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Infliximab maintenance therapy for fistulizing Crohn's disease

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.

P304

80-89

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2036.2006.03066.X

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

24 Suppl 3

http://www.w3.org/2001/XMLSchema#string

P577

2006-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6828335

http://www.w3.org/2001/XMLSchema#string

P698

16961751

http://www.w3.org/2001/XMLSchema#string

P921

Crohn's disease

Review article: biological drugs in Crohn's disease.

about

P2860

P2860

Review article: biological drugs in Crohn's disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P5875

P698

P921